Plasma free fatty acid levels and the risk of ischemic heart disease in men: prospective results from the Québec Cardiovascular Study


      Insulin resistance, through numerous related disturbances in glucose and lipoprotein-lipid metabolism, is associated with an increased risk of ischemic heart disease (IHD). The purpose of the present study was to examine the relationship between increased plasma free fatty acid (FFA) concentrations, as a feature of the insulin resistance syndrome, and the risk of IHD in men. Analyses were carried out in a nested, case-control sample of men selected from a population of 2103 individuals without IHD at baseline among whom 114 developed IHD during a 5-year follow-up period. Incident IHD cases were matched with controls for age, body mass index, smoking habits and alcohol intake. Analyses were performed while excluding (88 cases and 98 controls) and including (103 cases and 99 controls) patients with type 2 diabetes. Among non-diabetic individuals, elevated plasma FFA concentrations (3rd tertile of the distribution) yielded a twofold increase in the risk of IHD (odds ratio [OR] 2.1, P=0.05) compared with lower plasma FFA levels (lowest tertile) after adjusting for non-lipid risk factors. Further adjustment for insulin, triglycerides, apolipoprotein B, HDL cholesterol and small dense LDL attenuated significantly the relationship between plasma FFA concentrations and the risk of IHD. High plasma FFA levels showed no synergism with selected features of the insulin resistance syndrome in determining the risk of IHD. Inclusion of diabetic subjects in the study did not improve FFA independent prognostic value to the risk of IHD. These results suggest that elevated plasma FFA concentrations are associated with an increased risk of IHD. However, a single fasting measurement of plasma FFA levels does not appear to improve our ability to predict IHD onset in men when information on other risk factors is considered.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Bressler P.
        • Bailey S.R.
        • Matsuda M.
        • DeFronzo R.A.
        Insulin resistance and coronary artery disease.
        Diabetologia. 1996; 39: 1345-1350
        • DeFronzo R.A.
        • Ferrannini E.
        Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease.
        Diabetes Care. 1991; 14: 173-194
        • Reaven G.M.
        • Chen Y.D.
        • Jeppesen J.
        • Maheux P.
        • Krauss R.M.
        Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles.
        J. Clin. Invest. 1993; 92: 141-146
        • Despres J.P.
        • Lamarche B.
        • Mauriege P.
        • et al.
        Hyperinsulinemia as an independent risk factor for ischemic heart disease.
        N. Engl. J. Med. 1996; 334: 952-957
        • Lamarche B.
        • Moorjani S.
        • Lupien P.J.
        • et al.
        Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a 5-year follow-up of men in the Quebec Cardiovascular Study.
        Circulation. 1996; 94: 273-278
        • Lamarche B.
        • Despres J.P.
        • Moorjani S.
        • et al.
        Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Quebec Cardiovascular Study).
        Am. J. Cardiol. 1995; 75: 1189-1195
        • Lamarche B.
        • Tchernof A.
        • Moorjani S.
        • et al.
        Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study.
        Circulation. 1997; 95: 69-75
        • Reaven G.M.
        Banting lecture 1988. Role of insulin resistance in human disease.
        Diabetes. 1988; 37: 1595-1607
        • Lamarche B.
        • Tchernof A.
        • Mauriege P.
        • et al.
        Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease.
        J. Am. Med. Assoc. 1998; 279: 1955-1961
        • Boden G.
        Role of fatty acids in the pathogenesis of insulin resistance and NIDDM.
        Diabetes. 1997; 46: 3-10
        • Boden G.
        • Chen X.
        • Ruiz J.
        • White J.V.
        • Rossetti L.
        Mechanisms of fatty acid-induced inhibition of glucose uptake.
        J. Clin. Invest. 1994; 93: 2438-2446
        • Boden G.
        • Chen X.
        Effects of fat on glucose uptake and utilization in patients with non- insulin-dependent diabetes.
        J. Clin. Invest. 1995; 96: 1261-1268
        • Lewis G.F.
        Fatty acid regulation of very low density lipoprotein production.
        Curr. Opin. Lipidol. 1997; 8: 146-153
        • Sniderman A.D.
        • Cianflone K.
        Metabolic disruptions in the adipocyte-hepatocyte fatty acid axis as causes of HyperapoB.
        Int. J. Obes. Relat. Metab. Disord. 1995; 19: S27-S33
        • Steinberg H.O.
        • Tarshoby M.
        • Monestel R.
        • et al.
        Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation.
        J. Clin. Invest. 1997; 100: 1230-1239
        • Frayn K.N.
        • Williams C.M.
        • Arner P.
        Are increased plasma non-esterified fatty acid concentrations a risk marker for coronary heart disease and other chronic diseases?.
        Clin. Sci. (Colch). 1996; 90: 243-253
        • Dagenais G.R.
        • Robitaille N.M.
        • Lupien P.J.
        • et al.
        First coronary heart disease event rates in relation to major risk factors: Quebec cardiovascular study.
        Can. J. Cardiol. 1990; 6: 274-280
        • Moorjani S.
        • Dupont A.
        • Labrie F.
        • et al.
        Increase in plasma high-density lipoprotein concentration following complete androgen blockage in men with prostatic carcinoma.
        Metabolism. 1987; 36: 244-250
        • Albers J.J.
        • Warnick G.R.
        • Wiebe D.
        • et al.
        Multi-laboratory comparison of three heparin-Mn2+ precipitation procedures for estimating cholesterol in high-density lipoprotein.
        Clin. Chem. 1978; 24: 853-856
        • Friedewald W.T.
        • Levy R.I.
        • Fredrickson D.S.
        Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.
        Clin. Chem. 1972; 18: 499-502
        • Laurell C.B.
        Electroimmuno assay.
        Scand. J. Clin. Lab. Invest. Suppl. 1972; 124: 21-37
        • Noma A.
        • Okabe H.
        • Kita M.
        A new colorimetric micro-determination of free fatty acids in serum.
        Clin. Chim. Acta. 1973; 43: 317-320
        • Tchernof A.
        • Lamarche B.
        • Prud'Homme D.
        • et al.
        The dense LDL phenotype. Association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men.
        Diabetes Care. 1996; 19: 629-637
        • Morgan C.R.
        • Lazarow A.
        Immunoassay of insulin: two antibody system. Plasma insulin levels in normal, subdiabetic rats.
        Diabetes. 1963; 12: 115-120
        • Thulaseedharan N.
        • Augusti K.T.
        Risk factors for coronary heart disease in noninsulin dependent diabetes mellitus (NIDDM).
        Indian Heart J. 1995; 47: 471-476
        • Hennig B.
        • Shasby D.M.
        • Spector A.A.
        Exposure to fatty acid increases human low density lipoprotein transfer across cultured endothelial monolayers.
        Circ. Res. 1985; 57: 776-780
        • Laughton C.W.
        • Ruddle D.L.
        • Bedord C.J.
        • Alderman E.L.
        Sera containing elevated nonesterified fatty acids from patients with angiographically documented coronary atherosclerosis cause marked lipid accumulation in cultured human arterial smooth muscle-derived cells.
        Atherosclerosis. 1988; 70: 233-246
        • Endresen M.J.
        • Tosti E.
        • Heimli H.
        • Lorentzen B.
        • Henriksen T.
        Effects of free fatty acids found increased in women who develop pre-eclampsia on the ability of endothelial cells to produce prostacyclin, cGMP and inhibit platelet aggregation.
        Scand. J. Clin. Lab. Invest. 1994; 54: 549-557
        • Lagrost L.
        • Florentin E.
        • Guyard-Dangremont V.
        • et al.
        Evidence for nonesterified fatty acids as modulators of neutral lipid transfers in normolipidemic human plasma.
        Arterioscler. Thromb. Vasc. Biol. 1995; 15: 1388-1396
        • Boden G.
        • Chen X.
        • Rosner J.
        • Barton M.
        Effects of a 48-h fat infusion on insulin secretion and glucose utilization.
        Diabetes. 1995; 44: 1239-1242
        • Carpentier A.
        • Mittelman S.D.
        • Lamarche B.
        • et al.
        Acute enhancement of insulin secretion by FFA in humans is lost with prolonged FFA elevation.
        Am. J. Physiol. 1999; 276: E1055-E1066
        • Langin D.
        • Holm C.
        • Lafontan M.
        Adipocyte hormone-sensitive lipase: a major regulator of lipid metabolism.
        Proc. Nutr. Soc. 1996; 55: 93-109
        • Bjorntorp P.
        Metabolic implications of body fat distribution.
        Diabetes Care. 1991; 14: 1132-1143
        • Bjorntorp P.
        ‘Portal’ adipose tissue as a generator of risk factors for cardiovascular disease and diabetes.
        Arteriosclerosis. 1990; 10: 493-496
        • Simon J.A.
        • Hodgkins M.L.
        • Browner W.S.
        • et al.
        Serum fatty acids and the risk of coronary heart disease.
        Am. J. Epidemiol. 1995; 142: 469-476
        • Siguel E.N.
        • Lerman R.H.
        Trans-fatty acid patterns in patients with angiographically documented coronary artery disease.
        Am. J. Cardiol. 1993; 71: 916-920
        • Salonen J.T.
        • Salonen R.
        • Penttila I.
        • et al.
        Serum fatty acids, apolipoproteins, selenium and vitamin antioxidants and the risk of death from coronary artery disease.
        Am. J. Cardiol. 1985; 56: 226-231